54 results about "M. pneumoniae" patented technology

The invention relates to the technical field of gene engineering, in particular to a nucleic acid composition, a kit and a detection method for simultaneously and rapidly detecting 16 respiratory tract pathogens. The method specifically comprises the following steps: detecting influenza A virus, influenza B virus, novel coronavirus (ORF1ab gene, N gene), haemophilus influenzae, universal human parainfluenza virus, respiratory syncytial virus, human metapneumovirus, enterovirus, mycoplasma pneumoniae, group A streptococcus, bordetella pertussis, common coronavirus, rhinovirus, bocavirus and adenovirus; a forward primer, a reverse primer and a specific fluorescent probe of streptococcus pneumoniae. Through the PCR reaction, whether respiratory tract pathogens exist or not can be rapidly detected from a specimen at the same time, typing identification of 16 respiratory tract pathogens is carried out at the same time, and compared with a single fluorescent quantitative PCR method, the method is more convenient and rapid, and the cost is lower.

The invention provides an electrochemical biosensor for detecting mycoplasma pneumoniae, the core of the electrochemical biosensor comprises a specific capture probe, and the nucleotide sequence of the specific capture probe is a complementary sequence of a 23S-5S rDNA spacer sequence (ITS) of the mycoplasma pneumoniae. In the preparation link, the porous membrane is used as a high-efficiency electron transmission channel, the process is remarkably simplified, and the reaction efficiency is improved. By virtue of a capture probe taking 23S-5S rDNA ITS as a target, the sensor is endowed with excellent specificity and high sensitivity, so that the sensor has excellent performance in complex biological sample detection, can accurately and efficiently recognize a target object and effectively avoids interference of other substances. The electrochemical biosensor is easy and convenient to operate and high in response speed, has wide application prospects in the fields of clinical diagnosis and rapid disease screening, can provide key technical support for timely diagnosis of mycoplasma pneumoniae infection, greatly meets the urgent requirements for rapid and accurate detection in clinical and practical application, and has good application prospects. The development process of a biological detection technology in the mycoplasma pneumoniae detection direction is powerfully promoted.

The invention discloses a rapid culture system of mycoplasma pneumoniae. The rapid culture system comprises a growth-promoting additive A, a growth-promoting additive B and a growth-promoting additive C, wherein the growth-promoting additive A is A549 cell lysis buffer; the growth promoting additive B is a mixture of deoxyribonucleoside triphosphate and / or ribonucleoside triphosphate. The rapid culture system can promote rapid growth and reproduction of the mycoplasma pneumoniae, fully meets the nutritional requirements and growth requirements of the mycoplasma pneumoniae, and is of great significance to isolated culture, enrichment culture, epidemic disease prevention and control and molecular diagnosis of the mycoplasma pneumoniae. The invention also provides a culture method of the mycoplasma pneumoniae. The invention also provides application of the rapid culture system of the mycoplasma pneumoniae in in-vitro cell culture of the mycoplasma pneumoniae.

The invention relates to a composition and a kit for detecting chlamydia pneumonia, mycoplasma pneumonia and respiratory adenovirus, the composition comprises a primer pair and a probe corresponding to the primer pair, the primer pair comprises a primer pair 1 aiming at the chlamydia pneumonia, a primer pair 2 aiming at the mycoplasma pneumonia and a primer pair 3 aiming at the respiratory adenovirus; the probes comprise a specific probe 1 aiming at chlamydia pneumonia, a specific probe 2 aiming at mycoplasma pneumonia and a specific probe 3 aiming at respiratory adenovirus. According to the invention, the optimal primer pair and probe combination is screened out from the designed six groups of specific primer pairs and probes, so that the requirement of high sensitivity is met, the detection result is highly accurate, the detection sensitivity can reach 1copies / reaction, and the anti-interference capability is relatively strong. The PCR amplification reagent in the kit is presented in the form of a freeze-dried product, can be stored at room temperature, and has stable performance within 12 months, and the detection sensitivity and precision meet the detection requirements.

The invention provides a binding protein specifically binding to mycoplasma pneumoniae P1 protein as well as a preparation method and application thereof, and relates to the technical field of biology. The binding protein contains a heavy chain variable region and a light chain variable region, wherein a complementary determining region of the heavy chain variable region comprises amino acid sequences consistent with VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown as SEQ ID NO.1; the complementarity determining region of the light chain variable region comprises amino acid sequences consistent with VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region as shown in SEQ ID NO.2 or 3. The binding protein has good specific binding capacity with the mycoplasma pneumoniae P1 protein, can be combined with mycoplasma pneumoniae whole bacteria, and can be used for detection of mycoplasma pneumoniae or mycoplasma pneumoniae P1 protein and detection and diagnosis of mycoplasma pneumoniae or mycoplasma pneumoniae infection.

The invention provides a kit for detecting drug-resistant mutation of mycoplasma pneumoniae based on RPA-CRISPR and application of the kit. The invention provides an RPA primer pair and a crRNA sequence for detecting the drug-resistant mutation A2063G site of the mycoplasma pneumonia 23s rRNA gene, an RPA-CRISPR / Cas13a detection system is established, the detection system formed by the primer pair and the crRNA can accurately detect the drug-resistant mutation A2063G site of the mycoplasma pneumonia 23s rRNA gene within 30-40 minutes under an isothermal condition, the sensitivity and the specificity are very high, and the detection system can be used for detecting the drug-resistant mutation A2063G site of the mycoplasma pneumonia 23s rRNA gene. Amplification detection can be completed only by performing isothermal amplification at the temperature of 39 DEG C without using a variable-temperature instrument like PCR (Polymerase Chain Reaction); in addition, a lateral flow immunochromatography test strip is further combined, so that the on-site instant detection of the mycoplasma pneumoniae drug-resistant mutation can be realized.

This application discloses a Mycoplasma pneumoniae P1 protein-binding protein, its preparation method, and its uses. The Mycoplasma pneumoniae P1 protein-binding protein includes an immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3 contained in VHH as shown in any one of SEQ ID NO: 1-8. The bivalent or multivalent nanobodies prepared using this Mycoplasma pneumoniae P1 protein-binding protein can effectively enhance their binding strength to antigens, providing a superior raw material for developing highly sensitive detection and diagnostic applications.

The invention discloses a primer probe set for qualitative detection of mycoplasma pneumoniae, an RAA-CHA detection kit and application, and belongs to the technical field of microbiological detection.The primer probe set comprises an upstream primer, a downstream primer, an upstream probe, a downstream probe and a downstream probe, the nucleotide sequence of the upstream primer is as shown in SEQ ID NO: 1, and the nucleotide sequence of the downstream primer is as shown in SEQ ID NO: 2; the nucleotide sequence of the downstream primer is as shown in SEQ ID NO: 2, and the 5'end of the downstream primer is modified by phosphorylation; the nucleotide sequence of the H1 hairpin probe is as shown in SEQ ID NO: 3, and two ends of the H1 hairpin probe are respectively modified with a fluorescence reporter group and a fluorescence quenching group; the nucleotide sequence of the H2 hairpin probe is as shown in SEQ ID NO: 4. According to the application, efficient, accurate and sensitive qualitative detection of the mycoplasma pneumoniae gene is realized through effective amplification and specific recognition of the mycoplasma pneumoniae gene.

The application belongs to the field of intelligent medical treatment, and particularly relates to a method for constructing a refractory mycoplasma pneumoniae pneumonia prediction model and equipment. The method comprises the following steps: acquiring a baseline time data set and a follow-up time label of a mycoplasma pneumoniae patient; inputting the image data set into a lung blood vessel segmentation model to obtain a lung blood vessel network, obtaining a total lung blood vessel volume based on the lung blood vessel network, and obtaining a blood vessel volume of different cross-sectional areas based on a cross-sectional area of the lung blood vessel network; inputting a ratio of the blood vessel volume of different cross-sectional areas to the total lung blood vessel volume into a machine learning model to obtain a prediction label, and obtaining a refractory mycoplasma pneumoniae pneumonia prediction model after iterative optimization of the machine learning model based on a difference between the prediction label and the follow-up time label. The application segments a lung CT image to obtain a blood vessel network diagram, quantitatively obtains a percentage of a blood vessel volume of different thicknesses in a total lung blood vessel volume, and constructs a refractory mycoplasma pneumoniae pneumonia prediction model based on an innovative feature extraction method.

The invention provides a nano antibody specifically bound with mycoplasma pneumoniae P1 protein or an antigen binding fragment thereof, which can specifically recognize and bind the mycoplasma pneumoniae P1 protein and has better affinity with the mycoplasma pneumoniae P1 protein. The mycoplasma pneumoniae P1 protein can be used for preparing products for diagnosing, preventing and / or treating mycoplasma pneumoniae P1 protein infection or diseases caused by the mycoplasma pneumoniae P1 protein infection, or detecting the existence or the level of the mycoplasma pneumoniae P1 protein in a sample.

The application relates to the technical field of detection of mycoplasma pneumoniae, in particular to a rapid detection pen for mycoplasma pneumoniae antibodies, which comprises a box body, one end of the box body is fixedly connected with a drawing cylinder, the other end of the box body is provided with a negative pressure device, a connecting hole is formed through the box body, the two ends of the connecting hole are respectively communicated with the negative pressure device and the drawing cylinder, an installation groove is formed in the box body, a through hole is formed through the installation groove and the connecting hole, a filter layer is fixedly installed in the installation groove, and a detection test paper is fixedly connected to the upper surface of the filter layer. In use, the nasal cavity under different conditions can be sampled by switching modes, and the nasal mucus is drawn into the connecting hole and flows into the installation groove by pressing the negative pressure device, the filter layer removes impurities, optimizes sample concentration, protects target substances and reduces interference, and then flows to the detection test paper for detection, so that the equipment is simple and convenient to use and is convenient to use at home.

The TaqMan fluorescent quantitative PCR method for detecting the mycoplasma ovipneumoniae, provided by the invention, has very high specificity, sensitivity and stability, can be used for screening and detecting mycoplasma ovipneumoniae positive samples in various clinical samples, and has the characteristics of simplicity and convenience in operation, short detection period and high detection efficiency.

The present invention relates to diagnosing and classifying respiratory tract infections based on the determined levels of TK1 protein in a body sample. Specifically, based on the determined levels of TK1 protein, respiratory tract infections can be diagnosed and classified as caused by Mycoplasma pneumoniae.

Provided is an immunogenic Mycoplasma pneumoniae polypeptide epitope, which is a polypeptide epitope derived from the key adhesion proteins P1, P30, P40 / 90 and P116 of type I and type II Mycoplasma pneumoniae, and / or the CARDS toxin thereof. Further provided is a recombinant protein, which contains one or more of the immunogenic Mycoplasma pneumoniae polypeptide epitopes. Further provided is a vaccine for preventing Mycoplasma pneumonia infections, which vaccine provides protection against at least one of type I and / or type II Mycoplasma pneumonia infections, and is characterized in that the vaccine contains the recombinant protein and is a vaccine capable of providing safe and effective protection against Mycoplasma pneumonia infections.

The invention belongs to the technical field of kits, and particularly relates to a mycoplasma pneumoniae antigen detection kit which comprises a test tube rack, a plurality of first grooves are formed in the test tube rack and used for containing reagent tubes and a box body, the box body is used for containing the test tube rack and a pressurization assembly, and the pressurization assembly is arranged in the test tube rack and used for containing the reagent tubes. By rotating an external threaded column, the external threaded column enters an internal threaded channel, gas in the internal threaded channel is extruded, air pressure is applied to the surface of a piston rod through an air channel and a second groove in sequence, and then the reagent tube is extruded and fixed. At the moment, the piston rod is ejected out of the second groove by the air pressure, enters the first groove and simultaneously contacts with the reagent tube, the air pressure is continuously increased, the air pressure applied to the piston rod enables the piston rod to extrude and fix the reagent tube, collision of the reagent tube in the first groove is prevented, noise is avoided, and damage of the reagent tube caused by collision is reduced.

The invention discloses an evaluation system and method for improving mycoplasma pneumoniae detection participation degree through relay detection, and belongs to the field of data analysis, and the system comprises a data collection module which is used for collecting behavior data of research people; the data preprocessing module is used for carrying out data cleaning, integration and preprocessing on the behavior data; the model training module is used for obtaining a participation degree evaluation model; the evaluation import module is used for acquiring an output result of the participation degree evaluation model and importing the output result into an evaluation database of researchers for clustering segmentation; and the task allocation module is used for adjusting and allocating the detection tasks according to the evaluation segmentation result of the researchers. According to the method and the device, the technical problem that an effective method for evaluating and intelligently improving the participation degree of mycoplasma pneumoniae detection is lacked in the prior art is solved, and the effects of quantitatively evaluating the participation degree of researchers through a data-driven machine learning model and optimizing task allocation according to the evaluation result are achieved; therefore, the overall efficiency and quality of mycoplasma pneumoniae detection are improved.

The application discloses a detection system of mycoplasma pneumoniae. According to the P1 gene of mycoplasma pneumoniae, RPA primers and crRNA required by a CRISPR system with LbCas12a as a core enzyme are designed and screened, an RPA system and a CRISPR system are established, the influence of each component of the CRISPR-LbCas12a system on the RPA system reaction and the influence of each component of the RPA system on each component of the CRISPR-LbCas12a system are tested, components are optimized according to the test results, and an RPA-LbCas12a integrated system capable of detecting a conserved fragment on the P1 gene of mycoplasma pneumoniae is established. The RPA-LbCas12a integrated system established in the application has high sensitivity, high detection efficiency, reduces nucleic acid pollution, and has a wide application prospect.

The invention discloses a mycoplasma hyopneumoniae ELISA (enzyme-linked immunosorbent assay) serum antibody detection method. The mycoplasma hyopneumoniae ELISA serum antibody detection method comprises the following steps: coating an ELISA plate with an antigen, sealing, incubating serum, incubating a second antibody and developing a substrate, wherein the antigen is purified Mhp336 protein. The invention also discloses a system for diagnosing swine mycoplasmal pneumonia. The mycoplasma hyopneumoniae ELISA serum antibody detection method disclosed by the invention has the characteristics of good repeatability, high specificity and high sensitivity.

The application discloses a mycoplasma pneumoniae 23S rRNA gene A2063G drug resistance mutation detection method based on a CRISPR-LbCas12a system and belongs to the technical field of molecular diagnosis. The detection method can accurately distinguish single base differences such as A2063 and G2063, effectively avoids mismatch, and ensures the accuracy of results. Relying on a one-step reaction of RPA and CRISPR, the total time consumption is less than 45 minutes, and the waiting time is significantly shortened. The whole reaction is carried out under constant temperature conditions, does not need to rely on complex equipment such as a thermal cycler, is easy to operate, is very suitable for the application of primary medical institutions and instant test scenes. The cost control advantage is outstanding, the reagent cost is about 1 / 50 of second-generation sequencing and 1 / 5 of fluorescent PCR, and the economy is extremely good. In addition, the application technology shows good multiplex detection potential and wide application prospect.

The invention discloses a primer probe set and a kit for mycoplasma pneumoniae nucleic acid detection and application of the primer probe set and the kit in a method for directly detecting mycoplasma pneumoniae without extraction, and belongs to the technical field of molecular biology detection. Comprising an upstream primer MP-F as shown in SEQ ID NO: 1, a downstream primer MP-R as shown in SEQ ID NO: 2 and a probe MP-P as shown in SEQ ID NO: 3. The mycoplasma pneumoniae type I and the mycoplasma pneumoniae type II can be efficiently and specifically detected, a fluorescent quantitative PCR detection method can be adopted, PCR detection can be directly carried out without nucleic acid extraction, the detection cost is reduced, the test operation is simplified, the detection time is shortened, meanwhile, high specificity and accuracy are guaranteed, the sensitivity is improved, and the detection cost is reduced. The kit can be used for detecting mycoplasma pneumoniae nucleic acid in a human throat swab.

The invention discloses a primer group for detecting mycoplasma pneumoniae and drug-resistant mutation thereof and application of the primer group, and belongs to the technical field of gene detection. The primer group is designed aiming at the A / G variation site of the 2063rd site of an MP 23S rRNA conserved region, and specifically comprises an MP primer pair and a drug-resistant mutation primer pair thereof. The kit prepared by the invention comprises the primer group, and further comprises heat-resistant RNase H2 enzyme and in-vitro immune nucleic acid lateral chromatography test paper. According to the application, the kit is combined with an rhPCR-NALF technology, high-resolution detection of MP and drug-resistant mutation thereof can be realized through two-tube reaction and one-time detection, then visualization of the detection result is realized by combining a lateral chromatography technology, and result interpretation and analysis are more efficient and convenient. The invention aims to provide a rapid detection method for MP and drug-resistant mutation thereof with high sensitivity and specificity, so as to promote clinical precise diagnosis and treatment.

The present invention discloses an evaluation system and method for improving the participation of Mycoplasma pneumoniae detection by relay detection, which belongs to the field of data analysis. The system includes: a data collection module for collecting behavioral data of a research population; a data preprocessing module for performing data cleaning, integration and preprocessing on the behavioral data; a model training module for obtaining a participation evaluation model; an evaluation import module for obtaining the output results of the participation evaluation model and importing them into the evaluation database of researchers for clustering and segmentation; and a task allocation module for adjusting and allocating detection tasks according to the evaluation and segmentation results of researchers. This application solves the technical problem of the lack of effective methods in the prior art for evaluating and intelligently improving the participation of Mycoplasma pneumoniae detection, and achieves the technical effect of quantitatively evaluating the participation of researchers through a data-driven machine learning model, and optimizing task allocation accordingly, thereby improving the overall efficiency and quality of Mycoplasma pneumoniae detection.

The invention relates to the technical field of mycoplasma pneumoniae detection, in particular to a mycoplasma pneumoniae antibody rapid detection pen which comprises a box body, one end of the box body is fixedly connected with an extraction cylinder, the other end of the box body is provided with negative pressure equipment, a connecting hole is formed in the box body in a penetrating mode, and the negative pressure equipment is connected with the extraction cylinder. A connecting hole is formed in the box body, the two ends of the connecting hole are communicated with negative pressure equipment and the extraction cylinder respectively, a mounting groove is formed in the box body, a through hole is formed between the mounting groove and the connecting hole in a penetrating mode, a filter layer is fixedly mounted in the mounting groove, and detection test paper is fixedly connected to the upper surface of the filter layer. Nasal cavities under different conditions can be sampled by changing modes, the negative pressure equipment is pressed to suck snot into the connecting hole and flow into the mounting groove, the filter layer removes impurities, optimizes sample concentration, protects target substances and reduces interference, and then the snot flows to the detection test paper to be detected. The equipment is simple and convenient to use and can be conveniently used at home.

This invention relates to the field of biomedical technology, specifically disclosing a three-component recombinant subunit vaccine composition for Mycoplasma pneumoniae and its application. The vaccine composition comprises key antigenic proteins of Mycoplasma pneumoniae (MP): P1 protein, P40 / 90 protein, and an E132A attenuated mutant of community-acquired respiratory distress syndrome (CARDS) toxin (CARDS-Mut), optionally combined with Al(OH)3 single adjuvant or Al(OH)3+CPG double adjuvant. The recombinant protein was successfully purified using a prokaryotic expression system, and validated in a mouse model. The vaccine induces high-titer specific IgG antibodies, significantly alleviates lung tissue pathological damage, reduces bacterial load, and inhibits inflammatory factor secretion after challenge, with good safety. This invention solves the problem of high toxicity of CARDS toxin, providing an efficient and safe vaccine strategy for the prevention and control of MP infection.

A kit of detecting Mycoplasma pneumoniae is provided, and the kit comprises a combination of primers and probe consisting of a forward primer, a reverse primer and a probe. The forward primer is selected from the group consisting of SEQ ID NO: 2-3 and complementary sequences thereof, the reverse primer is selected from the group consisting of SEQ ID NO: 6-8 and complementary sequences thereof, and the probe is SEQ ID NO: 9 or a complementary sequence thereof. A method for detecting Mycoplasma pneumoniae using the above kit is also provided.

The invention is applicable to the technical field of biological detection, and provides a primer probe group, system and method for simultaneously detecting mycoplasma pneumoniae and chlamydia pneumoniae, specific primers and probes are designed aiming at conserved regions of 16S rRNA gene of MP and MOMP gene of CP, the two probes are respectively marked with FAM and ROX fluorophores, and the specific primers and probes can be used for simultaneously detecting mycoplasma pneumoniae and chlamydia pneumoniae. Parallel detection of MP and CP nucleic acids can be realized in a single reaction tube. The detection system provided by the invention comprises the PCR enhancer, so that the detection sensitivity and the amplification efficiency are effectively improved. The method further comprises an optimized nucleic acid extraction step and a reaction procedure, has the advantages of being easy and convenient to operate, rapid in detection, high in sensitivity and high in specificity and is suitable for early-stage rapid diagnosis of clinical respiratory tract samples.

The invention provides an MP primer group, a kit and application of the MP primer group in mycoplasma pneumoniae nucleic acid detection, and relates to the technical field of mycoplasma pneumoniae detection. The MP primer group comprises at least one of a first primer group and a second primer group; the first primer group consists of a pair of outer primers F3-1 and B3-1, a pair of inner primers FIP-1 and BIP-1, and a pair of loop primers LF-1 and LB-1; and the second primer group consists of a pair of outer primers F3-2 and B3-2, a pair of inner primers FIP-2 and BIP-2, and a pair of loop primers LF-2 and LB-2. According to the MP primer group provided by the invention, the specificity and the flexibility of detection are improved, the reliability is ensured, and the sensitivity is improved by increasing the amplification speed. The constant temperature characteristic of the LAMP technology reduces cross contamination, so that the detection is rapid and safe, and the LAMP technology is suitable for on-site rapid diagnosis.

The invention provides a lung inflammation postoperative prediction system based on mycoplasma pneumoniae infection, and relates to the technical field of mycoplasma pneumoniae and computers. The postoperative prediction system comprises a data acquisition module used for collecting basic information of a patient, clinical data after a lung inflammation operation, imaging data and biomarkers; the feature extraction and processing module is used for carrying out standardization and normalization processing on the collected clinical data, extracting key features and carrying out data cleaning, and meanwhile, the module also comprises an image processing module for carrying out image processing on the iconography data; and the multi-dimensional data fusion module is used for carrying out fusion analysis on the multi-dimensional data by utilizing an advanced machine learning algorithm and constructing a postoperative prognosis evaluation model. Through comprehensive consideration of clinical data, iconography data, genome data and other information of the patient, the limitation of a traditional single-index prediction method is broken through, and the accuracy and individuation of prognosis prediction are improved.

The invention discloses a mycoplasma pneumoniae gene detection kit based on a silicon-based micro-fluidic chip and a detection method thereof, and the kit provided by the invention comprises a rapid hot start DNA polymerase, a PCR reaction mixed solution, a positive reference substance and a negative reference substance, and also comprises a PCR reaction system which takes a mycoplasma pneumoniae repMp1 gene as a target gene, the following primers are designed by a PCR (Polymerase Chain Reaction) fluorescent probe method: an upstream primer F, a downstream primer R and a detection probe P, and the nucleotide sequences of the upstream primer F, the downstream primer R and the detection probe P are shown as SEQ ID NO.1-3. The mycoplasma pneumoniae gene detection method provided by the invention comprises the steps of extraction of pathogen DNA (Deoxyribonucleic Acid) and PCR (Polymerase Chain Reaction) amplification detection. According to the invention, the mycoplasma pneumoniae gene detection kit which is more comprehensive in detection effect, high in specificity, good in sensitivity, low in omission ratio, convenient, simple and easy to operate is provided.

The invention belongs to the technical field of biomedical engineering, and discloses light chain and heavy chain variable regions of an anti-mycoplasma pneumoniae monoclonal antibody and application of the light chain and heavy chain variable regions, and the light chain and heavy chain variable regions comprise light chain and heavy chain variable regions of monoclonal antibodies SPPHMP-No.5 and SPPHMP-No.19. The mycoplasma pneumoniae antigen colloidal gold detection kit can be applied to detection method application scenes such as immunochromatography (latex particles, immunofluorescence and colloidal gold), immunoturbidimetry, (electrochemiluminescence) and enzyme-linked immunosorbent assay; the kit adopts a double-antibody sandwich method to detect mycoplasma pneumonia, has the advantages of high sensitivity, strong specificity, quick detection, simplicity and convenience in operation, macroscopic result judgment, convenience in storage and transportation and the like, and is suitable for on-site quick detection of early mycoplasma pneumonia infection of clinical respiratory tract patients in pediatrics, respiratory medicine and the like. And pathogenesis screening of screening, prognosis and the like of a mycoplasma pneumoniae carrier or an incubation period patient by a basic unit and clinical treatment guidance.